UNLABELLED: In vivo imaging of human epidermal growth factor receptor type 2 (HER2) expression may allow direct assessment of HER2 status in tumor tissue and provide a means to quantify changes in receptor expression after HER2-targeted therapies. This work describes the in vivo characterization of the HER2-specific N-2-(4-(18)F-fluorobenzamido)ethyl]maleimide ((18)F-FBEM)-Z(HER2:342) Affibody molecule and its application to study the effect of 17 (dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) on HER2 expression by PET. METHODS: To assess the correlation of signal observed by PET with receptor expression, we administered the tracer to athymic nude mice bearing subcutaneous human breast cancer xenografts with different levels of HER2 expression. To study the downregulation of HER2, we treated the mice with 4 doses (40 mg/kg) of 17-DMAG, an inhibitor of heat-shock protein 90, known to decrease HER2 expression. The animals were scanned before and after treatment. After the last scan, the mice were euthanized and tumors were frozen for receptor analysis. RESULTS: The tracer was eliminated quickly from the blood and normal tissues, providing high tumor-to-blood and tumor-to-muscle ratios as early as 20 min after injection. The high-contrast images between normal and tumor tissue were recorded for BT474 and MCF7/clone18 tumors. Low but still detectable uptake was observed for MCF7 tumors, and none for MDA-MB-468. The signal correlated with the receptor expression as assessed by immunohistochemistry, Western blot, and enzyme-linked immunosorbent assay. The levels of HER2 expression estimated by post-treatment PET decreased 71% (P < 4 x 10(-6)) and 33% (P < 0.002), respectively, for mice bearing BT474 and MCF7/clone18 tumors. These changes were confirmed by the biodistribution studies, enzyme-linked immunosorbent assay, and Western blot. CONCLUSION: Our results suggest that the described (18)F-FBEM-Z(HER2:342) Affibody molecule can be used to assess HER2 expression in vivo by PET and monitor possible changes of receptor expression in response to therapeutic interventions.
UNLABELLED: In vivo imaging of human epidermal growth factor receptor type 2 (HER2) expression may allow direct assessment of HER2 status in tumor tissue and provide a means to quantify changes in receptor expression after HER2-targeted therapies. This work describes the in vivo characterization of the HER2-specific N-2-(4-(18)F-fluorobenzamido)ethyl]maleimide ((18)F-FBEM)-Z(HER2:342) Affibody molecule and its application to study the effect of 17 (dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) on HER2 expression by PET. METHODS: To assess the correlation of signal observed by PET with receptor expression, we administered the tracer to athymic nude mice bearing subcutaneous humanbreast cancer xenografts with different levels of HER2 expression. To study the downregulation of HER2, we treated the mice with 4 doses (40 mg/kg) of 17-DMAG, an inhibitor of heat-shock protein 90, known to decrease HER2 expression. The animals were scanned before and after treatment. After the last scan, the mice were euthanized and tumors were frozen for receptor analysis. RESULTS: The tracer was eliminated quickly from the blood and normal tissues, providing high tumor-to-blood and tumor-to-muscle ratios as early as 20 min after injection. The high-contrast images between normal and tumor tissue were recorded for BT474 and MCF7/clone18 tumors. Low but still detectable uptake was observed for MCF7 tumors, and none for MDA-MB-468. The signal correlated with the receptor expression as assessed by immunohistochemistry, Western blot, and enzyme-linked immunosorbent assay. The levels of HER2 expression estimated by post-treatment PET decreased 71% (P < 4 x 10(-6)) and 33% (P < 0.002), respectively, for mice bearing BT474 and MCF7/clone18 tumors. These changes were confirmed by the biodistribution studies, enzyme-linked immunosorbent assay, and Western blot. CONCLUSION: Our results suggest that the described (18)F-FBEM-Z(HER2:342) Affibody molecule can be used to assess HER2 expression in vivo by PET and monitor possible changes of receptor expression in response to therapeutic interventions.
Authors: Anna Orlova; Vladimir Tolmachev; Rikard Pehrson; Malin Lindborg; Thuy Tran; Mattias Sandström; Fredrik Y Nilsson; Anders Wennborg; Lars Abrahmsén; Joachim Feldwisch Journal: Cancer Res Date: 2007-03-01 Impact factor: 12.701
Authors: Tove Olafsen; Vania E Kenanova; Gobalakrishnan Sundaresan; Anne-Line Anderson; Desiree Crow; Paul J Yazaki; Lin Li; Michael F Press; Sanjiv S Gambhir; Lawrence E Williams; Jeffrey Y C Wong; Andrew A Raubitschek; John E Shively; Anna M Wu Journal: Cancer Res Date: 2005-07-01 Impact factor: 12.701
Authors: Eskender Mume; Anna Orlova; Barbro Larsson; Ann-Sofie Nilsson; Fredrik Y Nilsson; Stefan Sjöberg; Vladimir Tolmachev Journal: Bioconjug Chem Date: 2005 Nov-Dec Impact factor: 4.774
Authors: Zhen Cheng; Omayra Padilla De Jesus; Mohammad Namavari; Abhijit De; Jelena Levi; Jack Matt Webster; Rong Zhang; Brian Lee; Faisal A Syud; Sanjiv Sam Gambhir Journal: J Nucl Med Date: 2008-04-15 Impact factor: 10.057
Authors: Smitha Reddy; Calvin C Shaller; Mohan Doss; Irina Shchaveleva; James D Marks; Jian Q Yu; Matthew K Robinson Journal: Clin Cancer Res Date: 2010-12-21 Impact factor: 12.531
Authors: Dawei Jiang; Hyung-Jun Im; Haiyan Sun; Hector F Valdovinos; Christopher G England; Emily B Ehlerding; Robert J Nickles; Dong Soo Lee; Steve Y Cho; Peng Huang; Weibo Cai Journal: Eur J Nucl Med Mol Imaging Date: 2017-03-06 Impact factor: 9.236
Authors: Ganesan Vaidyanathan; Darryl McDougald; Jaeyeon Choi; Eftychia Koumarianou; Douglas Weitzel; Takuya Osada; H Kim Lyerly; Michael R Zalutsky Journal: J Nucl Med Date: 2016-02-18 Impact factor: 10.057
Authors: Jason H Sakamoto; Anne L van de Ven; Biana Godin; Elvin Blanco; Rita E Serda; Alessandro Grattoni; Arturas Ziemys; Ali Bouamrani; Tony Hu; Shivakumar I Ranganathan; Enrica De Rosa; Jonathan O Martinez; Christine A Smid; Rachel M Buchanan; Sei-Young Lee; Srimeenakshi Srinivasan; Matthew Landry; Anne Meyn; Ennio Tasciotti; Xuewu Liu; Paolo Decuzzi; Mauro Ferrari Journal: Pharmacol Res Date: 2010-01-05 Impact factor: 7.658
Authors: Max A Kruziki; Brett A Case; Jie Y Chan; Elizabeth J Zudock; Daniel R Woldring; Douglas Yee; Benjamin J Hackel Journal: Mol Pharm Date: 2016-10-10 Impact factor: 4.939
Authors: Jason P Holland; Eloisi Caldas-Lopes; Vadim Divilov; Valerie A Longo; Tony Taldone; Danuta Zatorska; Gabriela Chiosis; Jason S Lewis Journal: PLoS One Date: 2010-01-25 Impact factor: 3.240